Where is RBQM Heading in The Future With AI?

Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM) in clinical trials. With experience at both CluePoints and Veeva, Young discusses AI’s role, transparency, and the future of risk management in clinical trials.

Guide

A Comprehensive Guide to Adaptive Site Monitoring

Blog

ICH E6(R3), Demystified Part 2 | Defining Critical-to-Quality

Ethical and Actionable Trial Outcomes ICH E6(R3) is more than just an update to Good Clinical...

Press Release

CluePoints Appoints New Chief People Officer to Support Next Phase of Global Growth

King of Prussia, PA – January 12, 2026 – CluePoints, provider of leading statistical and AI-driven...

Blog

ICH E6(R3), Demystified: Turning Guidance into Oversight | Part 1

The New Era of Good Clinical Practice: A Practical Guide for Sponsors and CROs The updated...